Status:
ACTIVE_NOT_RECRUITING
SGLT2-inhibitors on PC-AKI
Lead Sponsor:
Shenyang Northern Hospital
Conditions:
Impact of SGLT2-inhibitors on PC-AKI in ACS Patients Receiving Invasive Strategy
Eligibility:
All Genders
18-80 years
Brief Summary
Percutaneous coronary intervention (PCI) is one of the most common invasive strategies employed in the diagnosis and treatment of coronary artery disease (CAD) patients. Invasive procedures necessitat...
Eligibility Criteria
Inclusion
- ACS patients undergoing invasive treatment (PCI or CAG)
- 18 \~ 80 years old adult patients
- Written informed consent provided
Exclusion
- Administration of any iodinated CM within 14 days before CAG or PCI
- Hepatic dysfunction (ALT 3 times greater than upper normal limit)
- Thyreoid insufficiency
- Renal artery Stenosis (unilateral \>70％ or bilateral stenosis\>50％)
- Known allergy to any of the study drugs or devices (iodinated CM, etc.)
- Pregnancy or lactation
- Contraindications for the use of SGLT-2 inhibitors, such as severe renal insufficiency (eGFR \<30 mL/min/1.73m2 or currently on dialysis), type 1 diabetes mellitus, severe infection, etc.)
- Any condition which might interfere with study compliance, or otherwise unsuitable for study participation as judged by the investigators
Key Trial Info
Start Date :
June 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 28 2026
Estimated Enrollment :
3600 Patients enrolled
Trial Details
Trial ID
NCT06491953
Start Date
June 1 2024
End Date
May 28 2026
Last Update
September 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
General Hospital of Northern Theater Command
Shenyang, Liaoning, China